AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase 2 study titled DESTINY-PanTumor02 to evaluate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) in treating ...

Methods: To evaluate serum HER2 (sHER2) as a potential biomarker for breast cancer response, we examined the serum samples from patients treated with neratinib or trastuzumab combined with paclitaxel ...

De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006) ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.